A multicenter retrospective study reported that a longitudinal MRI “habitat” model predicts pathological complete response to neoadjuvant chemoimmunotherapy in head and neck cancer. The model used changes in imaging habitat characteristics over time, aiming to differentiate responders from non-responders. If validated prospectively, the approach could refine treatment planning in a disease area where intensification and de-escalation decisions depend on early predictors. The focus on pathological complete response aligns the imaging endpoint with a clinically meaningful outcome. For imaging and translational biotech, the key contribution is methodological: a temporal MRI framework designed for response forecasting rather than static baseline staging.